MindMed Reports 2023 Financial Results and Business Updates
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Business Wire
--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)----Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024----Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)----Conference call to discuss year-end financial results at 8:00 a.m. EST-- NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.“2023 was a highly productive year for MindMed, which concluded with positive Phase 2b results for MM120 in the treatment of adult patients with GAD,” said Rob Barro
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New YorkBusiness Wire
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business UpdateBusiness Wire
- Bayridge Forms Advisory Council and Appoints Timothy Henneberry as Inaugural Member [Yahoo! Finance]Yahoo! Finance
- MindMed to Present at Upcoming May Medical ConferencesBusiness Wire
- This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher [Yahoo! Finance]Yahoo! Finance
MNMD
Earnings
- 11/2/23 - Beat
MNMD
Sec Filings
- 4/30/24 - Form 424B3
- 4/30/24 - Form 424B3
- 4/30/24 - Form EFFECT
- MNMD's page on the SEC website